ReviewNature reviews. Endocrinology2010
Adjunct therapy for type 1 diabetes mellitus.
Review in Nature reviews. Endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01722266 (Liraglutide in the Treatment of Type 1 Diabetes Mellitus), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy.Diabetologia · 2012Trial
- Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy.Journal of diabetes science and technology · 2011Trial
- Incretin-Based Adjunct to Background Insulin Treatment for Managing Body Weight Excess in Type 1 Diabetes: An Expert Opinion Viewpoint From the Italian Association of Clinical Endocrinologists.Diabetes/metabolism research and reviews · 2025Review
- A temperature-responsive dual-hormone foam nanoengine improves rectal absorptivity of insulin-pramlintide for diabetes treatment.Science advances · 2024Article
- Review
- Differential Effects of Aromatic Residues on Amyloid Formation and Cytotoxicity of Human IAPP.Biochemistry · 2022Article
- Engineering biopharmaceutical formulations to improve diabetes management.Science translational medicine · 2021Review
- Bee Pollen Polysaccharide FromFrontiers in pharmacology · 2021Article
- SGLT inhibitors as antidiabetic agents: a comprehensive review.RSC advances · 2020Review
- Pharmacological Treatment in Diabetes Mellitus Type 1 - Insulin and What Else?International journal of endocrinology and metabolism · 2018Review
- The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.Diabetes care · 2016Article
- Polycystic Ovary Syndrome May Be an Autoimmune Disorder.Scientifica · 2016Review
- Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology.Journal of diabetes research · 2016Review
- Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory.Nutrition & metabolism · 2016Article
- Personalized medicine in diabetes mellitus: current opportunities and future prospects.Annals of the New York Academy of Sciences · 2015Review
- Short-term insulin requirements following gastric bypass surgery in severely obese women with type 1 diabetes.Obesity surgery · 2014Article
- A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice.Nature communications · 2013Article
- Mechanisms of current therapies for diabetes mellitus type 2.Advances in physiology education · 2012Review
- Type 2 diabetes mellitus--current therapies and the emergence of surgical options.Nature reviews. Endocrinology · 2011Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin replacement therapy in type 1 diabetes mellitus (T1DM) is nonphysiologic. Hyperinsulinemia is generated in the periphery to achieve normal insulin concentrations in the liver. This mismatch results in increased hypoglycemia, increased food intake with weight gain, and insufficient regulation of postprandial glucose excursions. Islet amyloid polypeptide is a hormone synthesized in pancreatic beta cells and cosecreted with insulin. Circulating islet amyloid polypeptide binds to receptors located in the hindbrain and increases satiety, delays gastric emptying and suppresses glucagon secretion. Thus, islet amyloid polypeptide complements the effects of insulin. T1DM is a state of both islet amyloid polypeptide and insulin deficiency. Pramlintide, a synthetic analog of islet amyloid polypeptide, can replace this hormone in patients with T1DM. When administered as adjunctive therapy to such patients treated with insulin, pramlintide decreases food intake and causes weight loss. Pramlintide therapy is also associated with suppression of glucagon secretion and delayed gastric emptying, both of which decrease postprandial plasma glucose excursions. Pramlintide therapy improves glycemic control and lessens weight gain. Agents that decrease intestinal carbohydrate digestion (alpha-glucosidase inhibitors) or decrease insulin resistance (metformin) might be alternative adjunctive therapies in T1DM, though its benefits are marginally supported by clinical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.